SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioLineRx Sells APHEXDA Royalty Rights for $5.6 Million

BioLineRx agreed to sell APHEXDA royalty rights to Soleus Capital for $5.6 million.

BLK

Related stories